mc2 tcr T cells
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 20, 2020 (NCT04729543)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Melanocortin receptor 2Immunity, passive
MC2R immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04729543 | Phase 1/Phase 2 (Phase 2) | Oct 20, 2020 | Dutch Cancer Society, Erasmus University Rotterdam, Ludwig Institute for Cancer Research, Stichting Coolsingel Rotterdam grant |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Stichting Coolsingel Rotterdam grant | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1